NeuroOne to Present at Oppenheimer Healthcare Conference, Highlighting Neurological Treatment Platform

NeuroOne Medical Technologies Corporation announced its participation in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference, where company leadership will provide updates on its neurological treatment platform. The virtual presentation scheduled for March 17, 2026, represents a significant opportunity for the medical technology company to communicate directly with institutional investors about its progress in transforming surgical care for neurological disorders. President and CEO Dave Rosa and CFO Ron McClurg will host one-on-one meetings with investors and deliver a company presentation focused on commercialization updates and pipeline milestones.

The conference appearance matters because NeuroOne's technology platform addresses critical needs in neurological care, where current treatment options often involve multiple invasive procedures with extended recovery times. The company's OneRF platform combines diagnostic and therapeutic functions, potentially reducing hospitalizations and surgical procedures while lowering healthcare costs. This integrated approach represents an important advancement in medical technology, particularly for patients suffering from conditions that have traditionally required separate diagnostic and treatment interventions.

NeuroOne's participation in the Oppenheimer conference provides insight into the company's strategic direction and commercialization progress for its FDA-cleared product families. The Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System for brain applications, and OneRF Trigeminal Nerve Ablation System collectively form a comprehensive platform for neurological care. The company's research and development efforts in drug delivery and spinal cord stimulation programs further expand its potential impact on patient outcomes across multiple neurological conditions.

The implications of NeuroOne's conference presentation extend beyond investor relations to the broader healthcare landscape. As the company advances its technology platform, it contributes to the evolution of minimally invasive neurological treatments that could transform standard care protocols. The virtual format of the Oppenheimer 36th Annual Healthcare MedTech & Services Conference allows for broader accessibility to NeuroOne's updates, potentially reaching healthcare professionals and stakeholders interested in neurological innovation. For more information about the conference, visit https://www.oppenheimer.com/conferences/healthcare-medtech-services.

NeuroOne's focus on improving surgical care options for neurological disorders addresses a significant healthcare challenge where traditional approaches often involve complex, multi-stage procedures with variable outcomes. The company's electrode technology platform offers high-definition precision that could enhance both diagnostic accuracy and therapeutic effectiveness. This technological advancement matters because it represents a shift toward integrated neurological care solutions that streamline treatment pathways while potentially improving patient recovery experiences and long-term outcomes.

The company's scheduled presentation at 1:20 p.m. Eastern Time will provide specific details about commercialization progress and pipeline development, offering valuable insights into the practical implementation of NeuroOne's technology in clinical settings. As medical technology continues to advance toward more integrated and minimally invasive solutions, NeuroOne's platform represents an important contribution to this evolution, particularly in the specialized field of neurological care where precision and combination functionality offer distinct advantages over traditional separate diagnostic and therapeutic approaches.